Diabetes mellitus and hepatocellular carcinoma: Comparison of Chinese patients with and without HBV-related cirrhosis

Table 2 Comparison of clinical classification, clinical stage and tumor nodus metastasis stage of hepatocellular carcinoma patients with cirrhosis (n = 122) and patients without cirrhosis (n = 102) n (%)

	Total patients (n = 224)	Patients with LC (n = 122)	Patients without LC (n = 102)	P value1
Clinical classification
Massive-type	134 (59.8)	52 (42.6)	82 (80.4)	< 0.001
Nodular-type	61 (27.2)	49 (40.2)	12 (11.8)	< 0.001
Small-type	15 (6.7)	13 (10.7)	2 (2.0)	0.010
Diffuse-type	14 (6.3)	8 (6.6)	6 (5.9)	0.835
Clinical Stage
Stage I	15 (6.7)	9 (7.4)	6 (5.9)	0.656
Stage II	95 (42.4)	44 (36.1)	51 (50.0)	0.036
Stage III	114 (50.9)	69 (56.6)	45 (44.1)	0.064
TNM stage
Stage I	11 (4.9)	8 (6.6)	3 (2.9)	0.212
Stage II	43 (19.2)	34 (27.9)	9 (8.8)	< 0.001
Stage III	76 (33.9)	30 (24.6)	46 (45.1)	0.001
Stage IV	94 (42.0)	50 (41.0)	44 (43.1)	0.745
T Stage
Stage 1-2	81 (36.2)	61 (50.0)	20 (19.6)	< 0.001
Stage 3-4	143 (63.8)	61 (50.0)	82 (80.4)	-
N Stage
Stage 0	194 (86.6)	110 (90.2)	84 (82.4)	0.087
Stage 1	30 (13.4)	12 (9.8)	18 (17.6)	-
M stage
Stage 0	130 (58.0)	72 (59.0)	58 (56.9)	0.745
Stage 1	94 (42.0)	50 (41.0)	44 (43.1)	-

¹Comparison of the 122 hepatocellular caecinoma (HCC) patients with hepatitis B virus-related cirrhosis and 102 HCC patients without cirrhosis, using Pearson χ² tests because the total number of cases was more than 40 and no cells had an expected count less than 5. TNM: Tumor nodus metastasis; LC: Liver cirrhosis.